Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
ImmunityBio, Inc. (NASDAQ: IBRX)
IBRX Stock Predictions and Ratings
WSX Rating:
STRONG BUY
WSX Forecast (1yr):
121%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
63.20%
IBRX Stock Analysis
IBRX
PE Ratio:
IBRX
PEG Ratio:
Not Available
IBRX
Forward EPS Growth (12 month):
0.00%
IBRX
PS Ratio:
53.3
IBRX
PSG Ratio:
0.3
IBRX
Forward Revenue Growth (12 month):
159.50%
IBRX Articles
No data was found